Breast Cancer News and reporting on breast cancer. Jan 24, 2023 Ibex Inks Deal With AstraZeneca, Daiichi Sankyo to Develop AI-Based HER2 Scoring Jan 23, 2023 Genetic Testing Challenges in Oncology: Patient With Pending Bill Has BRCA1 Result Withheld Jan 19, 2023 Gene Signature Beats TILs as Biomarker of Response to Anti-HER2 Therapy Premium Jan 18, 2023 Penn Scientists Testing Out CAR T-Cell Therapy Gel to Prevent Breast Cancer Recurrence Post-Surgery Premium Jan 11, 2023 Bio4t2 Begins Dosing Solid Tumor Patients in First-In-Human CAR T-Cell Therapy Trial Jan 9, 2023 Ideaya to Launch PARG Inhibitor Trial in Homologous Recombination Repair-Deficient Cancers Jan 6, 2023 Immune Signatures Outperform TILs for HER2-Positive Breast Cancer Prognoses Jan 4, 2023 Gene Expression Score IDs Breast Cancer Patients Responsive to Histone Deacetylase 6 Inhibitor Premium Dec 21, 2022 Guardant Health, Susan G. Komen Partner to Evaluate MRD Test in Breast Cancer Dec 20, 2022 NICE Backs Enhertu via Managed Access Program for Certain HER2-Positive Breast Cancer Patients Dec 19, 2022 Carrick Therapeutics, Menarini Group Studying Samuraciclib With Elacestrant Dec 16, 2022 Everything Genetic, Berkshire and Surrey Pathology Services Jointly Launch Cancer NGS Service in UK Dec 14, 2022 Functional Precision Medicine Firm Kiyatec Raises $18M in Series C Funding Round Dec 14, 2022 NewStem, MSK Innovation Hub Team to Validate Cancer Diagnostics Software Platform Dec 12, 2022 NeoGenomics Growing Evidence Base for Residual Disease Assay in Breast Cancer Premium Dec 12, 2022 Myriad Genetics Generates More Data on its PRS's Ability to Identify Who Will Develop Breast Cancer Premium Dec 10, 2022 Regeneron's Dual Immunotherapy Cocktail Shows Promise as Neoadjuvant Breast Cancer Option Premium Dec 9, 2022 Exact Sciences Takes Aim at Radiotherapy Response Prediction With New Gene Expression Data Premium Dec 9, 2022 Guardant Health, AstraZeneca Partner on Liquid Biopsy CDx for Breast Cancer Drug Dec 9, 2022 Breast Cancer Patients Fare Better on Elacestrant With Longer CDK4/6 Inhibitor Treatment Load More Breaking News Ratio Therapeutics Raises $20M in Series A Financing Guardant Health, AnHeart Tx to Develop Blood- and Tissue-Based CDx for NSCLC Drug Ellipses Pharma Cleared by FDA to Open Phase I/II AML Trial Survey Reveals Changing Genetic Testing Patterns, Persistent Disparities in Precision Oncology Amgen's Lumakras Sales Increased 58 Percent in Q4 2022 Coeptis Therapeutics, University of Pittsburgh Studying SNAP-CAR Therapy in HER2-Positive Cancers
